तुलना करने के लिए मीट्रिक्स | ACTI | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधACTIपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −5.5x | −1.6x | −0.5x | |
PEG अनुपात | −0.08 | −0.04 | 0.00 | |
क़ीमत/बुक | 4.0x | 1.7x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 13.6x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 247.2% | 144.1% | 55.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | 27.0% | 7.2% | अनलॉक करें |
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvironment which is in phase I/II for the treatment of hematological cancers, such as myelofibrosis and multiple myeloma; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas ans Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.